Investing.com UK - Financial Markets Worldwide
NVDA gained a massive 197% since our AI first added it in November - is it time to sell? 🤔Read more

Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development

Published 28/03/2022, 18:46
© Reuters. Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development
VSTM
-

Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for up to $150 million to primarily support the continued development, commercial preparation, and potential launches of VS-6766 and defactinib.

  • Verastem drew an initial $25 million term loan at closing. The Company can access up to an additional $125 million in a series of tranches, $75 million of which are based on certain pre-determined milestones and $50 million at the lender's discretion.
  • Related: Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why.
  • The Company had cash, cash equivalents, and an investment balance of $100.3 million. Considering the initial drawdown of $25.0 million at closing, the Company would have had a pro-forma cash balance of $125.3 million and an expected cash runway through 2025.
  • The Company posted a Q4 FY21 EPS loss of $(0.08), down from (0.09) a year ago.
  • Price Action: VSTM shares are up 8.82% at $1.30 during the market session on the last check Monday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.